Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Rewey Asset Management Chip Rewey | “OFIX was our weakest performer in 1Q26, as the stock declined following its May 21st announcement that CMS had lowered its reimbursement for non-invasive bone growth stimulator devices. Due to the change OFIX reduced its revenue guidance by $5 million for 2026 and withdrew its prior 3-year targets. While clearly a disappointment, this news was not a company driven negative. We still forecast revenue and earnings growth for OFIX over the next few years and believe the share decline is overdone. Incredibly, on July 1st, CMS completely reversed this code change, a net positive for OFIX.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Rewey Asset Management Chip Rewey | “In 2Q25, we increased our position in Orthofix Medical, Inc. (OFIX) following a 45.6% decline from its February high and a 36.1% drop from its 2024 close. We view this as a compelling valuation opportunity, supported by recent insider purchases by its CEO and also by its top shareholder, a 13D filer. We believe Orthofix's strong financial position should continue to improve throughout 2025, as it is largely complete with the integration of its Seaspine merger. In November 2024, OFIX extended its credit agreement through 2029, with net debt to adjusted EBITDA at 1.2x and $115 million in undrawn capacity. On its 1Q25 call, management reaffirmed guidance for positive free cash flow in 2025, with further improvement expected in 2026 and 2027. We believe part of OFIX's 2Q25 share weakness stemmed from a $10 million reduction in annual revenue guidance given on its 1Q25 call, driven by one-time factors rather than a slowdown in long-term growth… We expect management to improve EBITDA margins to the mid-teens by 2027… We think the 2025 sell-off in the shares has created a compelling valuation opportunity…13 BSD Analysis: Orthofix is a high-growth MedTech restructuring story whose value is locked in the successful integration of its recent major merger. The core moat is its comprehensive portfolio of musculoskeletal pathology solutions, spanning spinal hardware, bone growth therapies, biologics, and specialized orthopedic solutions. The entire investment thesis is a bet on the new, integrated structure maximizing the value of its offerings, including the advanced 7D FLASH™ navigation system. Management is focused on leveraging its combined scale to drive operating synergies and gain market share in the non-cyclical, high-margin orthopedic and spine markets. Successful execution of the post-merger integration is the single, high-conviction catalyst for a major re-rating.” | BULL | Q2 2025 Jul 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
